CAJ | 학술논문

目的评估云南白药胶囊联合复方环丙沙星栓对NIH-Ⅲ A型前列腺炎患者的治疗效果.方法将70例临床诊断为NIH-Ⅲ A型前列腺炎患者按治疗方式的不同随机分为对照组(Group 1)和试验组(Group 2).试验组35例患者接受云南白药胶囊联合复方环丙沙星栓治疗(复方环丙沙星栓1枚/次,2次/d,塞肛;云南白药胶囊2粒/次,3次/d),对照组35例患者接受复方环丙沙星栓治疗(复方环丙沙星栓1枚/次,2次/d,塞肛),两组患者连续治疗12周.收集患者入组前的人口统计学资料及基线资料;所有患者在初始入组以及治疗结束时要求填写NIH-CPSI(慢性前列腺炎症状指数评分表),分别记录总的CPSI评分、疼痛症状评分、排尿症状评分以及生活质量评分.分别应用配对t检验、成组样本t检验分析治疗前后组内以及组间上述各评分的变化.结果两组间的人口学特征以及基线资料相似.治疗前后两组组内CPSI总评分以及各分类评分的差异均存在显著的统计学意义(P＜0.05).组间比较显示治疗后试验组CPSI以及各分类评分的变化率明显高于对照组,差异存在显著的统计学意义(P＜0.05).结论复方环丙沙星栓可以明显改善NIH-Ⅲ A型前列腺炎患者的症状,降低CPSI总评分以及分类评分;云南白药胶囊可以增强前者的治疗效果.
목적 평고운남백약효낭연합복방배병사성전대NIH-Ⅲ A형전렬선염환자적치료효과.방법 장70례림상진단위NIH-Ⅲ A형전렬선염환자안치료방식적불동수궤분위대조조(Group 1)화시험조(Group 2).시험조35례환자접수운남백약효낭연합복방배병사성전치료(복방배병사성전1매/차,2차/d,새항;운남백약효낭2립/차,3차/d),대조조35례환자접수복방배병사성전치료(복방배병사성전1매/차,2차/d,새항),량조환자련속치료12주.수집환자입조전적인구통계학자료급기선자료;소유환자재초시입조이급치료결속시요구전사NIH-CPSI(만성전렬선염증상지수평분표),분별기록총적CPSI평분、동통증상평분、배뇨증상평분이급생활질량평분.분별응용배대t검험、성조양본t검험분석치료전후조내이급조간상술각평분적변화.결과 량조간적인구학특정이급기선자료상사.치료전후량조조내CPSI총평분이급각분류평분적차이균존재현저적통계학의의(P＜0.05).조간비교현시치료후시험조CPSI이급각분류평분적변화솔명현고우대조조,차이존재현저적통계학의의(P＜0.05).결론 복방배병사성전가이명현개선NIH-Ⅲ A형전렬선염환자적증상,강저CPSI총평분이급분류평분;운남백약효낭가이증강전자적치료효과.
Objectives To evaluate the efficacy of Yunnan Baiyao(YB) capsules combined with Compound Ciprofloxacin Suppository(CCS) in the treatment of NIH-ⅢA Prostatitis.Methods 70 patients affected by NIH-ⅢA Prostatitis were prospectively included in our study for multimodal drug therapy for 12 weeks.35 patients were randomized to monotherapy CCS (Group 1),while 35 patients were assigned to CCS combined with YB capsules (Group 2).NHI-CPSI questionnaires before and after treatment were recorded as well as demographics and baseline characteristics.Paired-samples T test and independent-samples T test were used to compare the above data.Results At 12 wks follow up,we observed a significant amelioration in NIH-CPSI total score and sub -scores in both Groups.Patients in Group 2 showed a significant improvement in the variation of NIH-CPSI total score and sub-scores when compared with Group 1.Conclusions A multimodal therapy,CCB,is of great efficiency in declining the NIH-CPSI total score and sub-scores of NIH-Ⅲ A Prostatitis patients.Yunnan Baiyao (YB) capsules may have great role in enhancing the therapeutic effect of CCB.